Axsome Therapeutics 的空头股数在 1 月份下跌了 13.1%，而 AxoGen 的涨幅为 20.4%。 Axsome Therapeutics' short interest fell 13.1% in January, contrasting with AxoGen's 20.4% rise.

1月,Axosome治疗公司短期利息下降13.1%,股票从几家经纪公司获得正面评级,平均为“机动购买”。 Axsome Therapeutics saw a 13.1% drop in short interest in January, with the stock receiving positive ratings from several brokerages, averaging to a "Moderate Buy." 该公司在其最新报告中还击败了对收益和收入的预期。 The company also beat earnings and revenue expectations in its latest report. AxoGen, 神经再生科技提供商, 短期兴趣提升20.4%, 股票升级为StockNews.com的“买买”评级。 Meanwhile, AxoGen, a nerve regeneration tech provider, saw a 20.4% rise in short interest, with its stock upgraded to a "buy" rating by StockNews.com.